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Neurotransmitter Signaling in White Matter
Arthur M. Butt,1 Robert F. Fern,2 and Carlos Matute3
White matter (WM) tracts are bundles of myelinated axons that provide for rapid communication throughout the CNS and
integration in grey matter (GM). The main cells in myelinated tracts are oligodendrocytes and astrocytes, with small popula-
tions of microglia and oligodendrocyte precursor cells. The prominence of neurotransmitter signaling in WM, which largely
exclude neuronal cell bodies, indicates it must have physiological functions other than neuron-to-neuron communication. A
surprising aspect is the diversity of neurotransmitter signaling in WM, with evidence for glutamatergic, purinergic (ATP and
adenosine), GABAergic, glycinergic, adrenergic, cholinergic, dopaminergic and serotonergic signaling, acting via a wide range
of ionotropic and metabotropic receptors. Both axons and glia are potential sources of neurotransmitters and may express
the respective receptors. The physiological functions of neurotransmitter signaling in WM are subject to debate, but gluta-
mate and ATP-mediated signaling have been shown to evoke Ca21 signals in glia and modulate axonal conduction. Experi-
mental findings support a model of neurotransmitters being released from axons during action potential propagation acting
on glial receptors to regulate the homeostatic functions of astrocytes and myelination by oligodendrocytes. Astrocytes also
release neurotransmitters, which act on axonal receptors to strengthen action potential propagation, maintaining signaling
along potentially long axon tracts. The co-existence of multiple neurotransmitters in WM tracts suggests they may have
diverse functions that are important for information processing. Furthermore, the neurotransmitter signaling phenomena
described in WM most likely apply to myelinated axons of the cerebral cortex and GM areas, where they are doubtless
important for higher cognitive function.
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Introduction
White matter (WM) is defined as a tract of myelinatedaxons—WM appears opaque or dense due to the fatty
myelin in anatomical sections and in brain scans. Notwith-
standing this, myelination is not restricted to WM and is also
critical to rapid communication and integration in grey mat-
ter (GM) areas, such as in axons in the cortical GM and hip-
pocampus. Hence, many aspects of neurotransmitter signaling
to be covered in this review have resonance in GM and
higher cognitive function. Indeed, in the human brain WM is
a prominent feature of the cerebral cortex, the seat of higher
intelligence. Myelination of GM is also evident in rodents,
but discrete WM tracts are not pronounced in the cerebral
cortex. As a general concept, WM are simply concentrations
of myelinated axons bundled together into tracts that inter-
connect areas of GM. The molecular physiology of myelin-
ated axons will be very similar in WM and GM, and they
will be subject to the same neurotransmitter signaling phe-
nomena that is the subject of this review. The main cells asso-
ciated with myelinated axons are the myelinating
oligodendrocytes and oligodendrocyte precursor cells (OPCs),
or NG2-glia (10–20% of oligodendrocyte lineage cells are
estimated to be OPCs), together with astrocytes and small
populations of microglia. In tracts such as the optic nerve,
most if not all axons are myelinated, whereas other tracts can
contain both myelinated and small diameter unmyelinated
axons. Astrocytes appear first in development, followed by
OPCs that differentiate into myelinating oligodendrocytes
mainly during the postnatal period, although they continue
to generate oligodendrocytes slowly throughout adult life; in
rodents, myelination in the forebrain continues until at least
6 to 12 months, and in the human cortex up until 50 years
of age, after which myelination declines. A major disease of
WM is Multiple sclerosis (MS), a demyelinating disease that
results in a devastating loss of function (Lassmann, 2014).
However, the incidence of stroke is far greater and the
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majority of strokes affect myelinated axons, which are also
the seat of developmental lesions associated with cerebral
palsy (Back and Rosenberg, 2014). In addition, myelin loss
or disruption are also primary pathological features of leuko-
dystrophies, as well as traumatic brain injury and spinal cord
injury (Kou and VandeVord, 2014), and is associated with
dementias (including Alzheimer’s disease) and neuropsycho-
logical diseases, such as bipolar disorder and schizophrenia
(Haroutunian et al., 2014).
One of the most commonly studied WM preparations
is the optic nerve, which connects the eye to the brain, and
to lesser extents the corpus callosum, which forms a large
commissure connecting the two hemispheres of the cerebrum,
and the dorsal column of the spinal cord. Notably, the optic
nerve does not contain neuronal cell bodies or synapses,
although this is not the case for all WM structures
(von Engelhardt et al., 2011). It is surprising that
neurotransmitter-mediated signaling is prominent in the optic
nerve and other WM areas studied, since neurotransmitter
signaling is generally considered to be an exclusive function
of neurons confined to synapses. Most evidence points to
major roles for glutamate and ATP, but numerous other neu-
rotransmitters are also implicated in WM signaling, including
GABA and norepinephrine (Fig. 1). There is a clear role for
glutamate and ATP in WM pathology, for example in ische-
mia and demyelination. In contrast, the primary physiological
functions of neurotransmitters in WM remain elusive. In this
review, we will focus on the potential physiological functions
of glutamate- and ATP-mediated signaling and provide an
overview of other key neurotransmitters.
Multiple Neurotransmitters are
Present in WM
Reports on the effects of neurotransmitters on WM are plen-
tiful, in particular during development. As described below,
isolated WM preparations show functional responses to a
variety of neurotransmitters, although localization of receptor
expression can be difficult. In vitro studies largely produced
in the 1980s reported numerous cases of astrocytes and/or
oligodendroglia that either responded to neurotransmitter
agonists or expressed receptor protein/mRNA (Domingues
et al., 2010; Hertz et al., 1984; Salm and McCarthy, 1989;
Williamson et al., 1998). However, caution must be used in
extrapolating what glial cells are capable of doing in culture
conditions from what they actually do in the CNS, and we
have compiled a list of glutamatergic/purinergic (Table 1) and
non-glutamatergic/purinergic WM receptor expression studies
(Tables 2 and 3), restricted to reports that have confirmed
FIGURE 1: Neurotransmitter signaling in white matter pathophysiology. White matter axons, macroglia, microglia, and myelin express a
large repertoire of neurotransmitter receptors whose functional significance remains elusive. Among them, ionotropic glutamate recep-
tors and P2X7 receptors have been partially characterized and their localization is relatively well known. Their activation leads to an
overall increase in cytosolic Ca21 which in pathological conditions can lead to primary or secondary glial cell death and axonal damage;
in particular, oligodendrocytes and their progenitors (OPC) are highly vulnerable to Ca21 overload. Under normal conditions (left), gluta-
mate is taken up by glutamate transporters and ATP readily degraded by ectoATPases which prevent overactivation of glutamate and
P2X7 receptors, respectively. In white matter injury (right), increased extracellular levels of glutamate and/or ATP, and other transmit-
ters, leads to overactivation of their receptors which can lead to injury (depicted in pink for oligodendrocytes and myelin). See text for
further details. Abbreviations: GluR, glutamate receptor; OPC, oligodendrocyte progenitor cell.
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expression in situ using established cell markers. In addition
to distinguishing types of glia, a reliable test for cell identifi-
cation is essential due to the presence of neuronal populations
in some WM structures (von Engelhardt et al., 2011),
although this is not true for the commonly used optic nerve
preparations.
Since the 1990s, it has been shown in a number of neo-
natal rodent WM preparations that glia showed Ca21 rises in
response to a wide range of neurotransmitters, including
adenosine, ATP, glutamate, histamine, GABA, norepineph-
rine, serotonin, angiotensin II, bradykinin, and substance P
(Bernstein et al., 1996; Kriegler and Chiu, 1993). In addi-
tion, electrophysiological criteria have been used to distin-
guish glial cell types, allowing the first descriptions of
functional glutamate, GABA-A and glycine receptors in iden-
tified astrocytes, oligodendrocytes, glioblasts and OPCs in situ
(Berger et al., 1992; Butt and Jennings 1994; Pastor et al.,
1995). However, in the intact tissue it is often difficult to dis-
tinguish between direct and indirect effects. For example, acti-
vation of adreno-receptors can be damaging to axonal
function and glial ultrastructure (Constantinou and Fern,
2009), but it is not clear whether the functional receptors are
on the glia or axons, or both. Several studies have attempted
to address this question by measuring changes in WM axon
excitability and membrane potentials. For example, the effects
of GABA-A receptor activation are associated with elevated
extracellular [K1] that may originate from glia, but experi-
mentally elevating [K1] does not duplicate the effects of
GABA upon excitability leading to the conclusion that
receptor expression is axonal (Sakatani et al., 1994). In
general, it may be assumed that the effects of neurotrans-
mitters on glial Ca21 and membrane properties appear to
be mediated largely by glial expression of neurotransmit-
ter receptors (Butt and Jennings, 1994; Hamilton et al.,
2008), whereas effects upon axonal excitability appear to
be mediated largely by axolemma expression, rather than
TABLE 2: Effects of Nonglutamatergic/Purinergic Receptor Activation in White Matter
Receptor type Effect Preparation Citation
GABA-A Axon depolarization and reduced
excitability
nRON (Constantinou and Fern, 2009;
Sakatani et al., 1991, 1992;
Sun and Chiu, 1999)
Rat SCDC (Honmou et al., 1993;
Sakatani et al., 1993)
Axon depolarization RON (Simmonds and Griffith, 1962)
Oligodendrocytes and glioblasts
depolarization
Neonatal mouse
corpus callosum
(Berger et al., 1992)
GABA-B Reduced activity-dependent Ca21
influx into axons
nRON (Sun and Chiu, 1999)
Increase ischemia-tolerance RON (Fern et al., 1994, 1995)
Glycine Reduced axon excitability nRON (Constantinou and Fern, 2009)
Axon depolarization RON (Simmonds and Griffith, 1962)
Nicotinic acetylcholine
receptor
Non-reversible excitability loss associated
with glial pathology
nRON (Constantinou and Fern, 2009)
Axonal Ca21 rise and reduced excitability nRON/nMON (Zhang et al., 2004)
Adreno-receptors Non-reversibly excitability loss, associated
with glial pathology (80 min application)
nRON (Constantinou and Fern, 2009)
Ischemic axon injury potentiation without
affecting excitability
Rat spinal cord (Nikolaeva et al., 2009)
Reversible increased excitability
(10 min application)
RON/SCDC (Honmou and Young, 1995)
a-receptor functionally coupled
to axonal G protein
Neonatal rat
white matter
(Sanders et al., 2005;
Venugopalan et al., 2006)
5-HT Modulation of axonal excitability Neonatal rat SCDC (Saruhashi et al., 1997)
Dopamine D1 receptors functionally coupled
to G protein
Rat spinal cord (Venugopalan et al., 2006)
nRON5 neonatal rat optic nerve, RON5mature rat optic nerve, MON5 mouse optic nerve SCDC5 spinal dorsal column.
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glial responses that subsequently modify excitability
(Nikolaeva et al., 2009; Sun and Chiu, 1999; Zhang
et al., 2004).
WM Synapses and Mechanisms of
Neurotransmitter Release
The old dogma that chemical synaptic specializations occur
exclusively between neurons was overturned by the discovery
of functional glutamatergic and GABAergic synapses between
axon terminals and OPCs in the hippocampus (Bergles et al.,
2000; Lin and Bergles, 2004). Notably, OPC in WM also
make occasional synapses with unmyelinated axons in an en
passant fashion (Etxeberria et al., 2010; Kukley et al., 2007;
Mangin and Gallo, 2011; Ziskin et al., 2007). Indeed, pre-
myelinated WM axons contain glutamate-laden vesicles and
the machinery for vesicular release (Alix et al., 2008),
although it is unclear whether this mechanism persists after
maturation. Thus, action potentials induce vesicular release of
glutamate (and possibly other neurotransmitters) from
unmyelinated axons in the corpus callosum and optic nerve
that activate AMPA-type glutamate receptors on OPC. In
addition, action potentials evoke Ca21 signals in astrocytes
and OPC in the optic nerve, most likely involving the release
of glutamate from axons that triggers the subsequent release
TABLE 3: In Situ Expression of Nonglutamatergic/Purinergic Receptors in White Matter Glia
Neurotransmitter Receptor type Preparation Citation
Astrocytes 5-HT 5-HT2A Rat spinal cord (Maxishima et al., 2001)
5-HT1A Primate spinal and
cortical WM
(Azmitia et al., 1996)
GABA GABA-A Neonatal rat spinal
cord WM
(Pastor et al., 1995)
GABA-A obligatory
b1 subunit
Cat cortical WM (Rosier et al., 1993)
GABA-A depolarization;
no effect of GABA-B
nRON (Butt and Jennings, 1994)
GABA-A Neonatal rat spinal
cord WM
(Pastor et al., 1995)
Glycine Neonatal rat spinal
cord WM
(Pastor et al., 1995)
Nor-adrenaline b2 Rat, rabbit, and
human ON
(Mantyh et al., 1995)
a2a Adult rat SCDC (Nikolaeva et al., 2009)
Oligodendrocytes 5-HT 5-HT2A Rat spinal cord (Maxishima et al., 2001)
GABA GABA-A Neonatal rat spinal
cord WM
(Pastor et al., 1995)
GABA-A depolarization MON (Butt and Tutton, 1992)
GABA-A patch-clamp Neonatal mouse WM (Berger et al., 1992)
Some GABA-B
immunoreactivity
in O41 cells
Neonatal mouse WM (Luyt et al., 2007)
GABA-B subtypes
immunoreactivity absent
from MBP1 cells
(but present in axons)
Adult rat spinal cord (Charles et al., 2003)
General immunoreactivity
of GABA-B1 cells
Rat white matter (Charles et al., 2001;
Margeta-Mitrovic
et al., 1999)
Glycine Patch-clamp Neonatal rat spinal
cord WM
(Pastor et al., 1995)
Glycine responses in myelin
via NMDA receptors
CNS myelin (Pina-Crespo et al., 2010)
Dopamine D3 on cell somata,
but not co-stained
CC mouse
nRON5 neonatal rat optic nerve, ON5optic nerve; SCDC5 spinal dorsal column.
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of ATP from astrocytes, involving a staggering array of iono-
tropic and metabotropic glutamate and purine (ATP) recep-
tors (Hamilton et al., 2008, 2010). To add to this complex
mosaic of signaling, axoglial synapses may also be modulated
by the vesicular release of glutamate and/or ATP from
astrocytes, as observed in classical neuron-to-neuron synapses
(Volterra and Meldolesi, 2005). Furthermore, OPC may also
express synaptophysin indicating they may have mechanisms
for transmitting as well as receiving signals (Hamilton et al.,
2010). In addition to vesicles, reversed uptake through trans-
porters has been described for glia and is equally possible for
axons (see below), and multiple potential mechanisms for
neurotransmitter release from astrocytes include gap junc-
tions, pannexins, P2X7 receptors, anion channels and stretch-
activated receptors (Parpura et al., 2004). Hence, WM axons
and glia have the potential for neurotransmitter release both
at axoglial “synapses” and by the less specific mechanism of
volume or “spillover” transmission through neurotransmitter
release into the extracellular space.
Glutamate Signaling in WM
Glutamate Receptor Subtypes
Glutamate acts via ionotropic receptors (iGluR), which gate
membrane ion channels permeable to cations, and metabo-
tropic receptors (mGluR), seven transmembrane (7TM)
receptors that are coupled to G proteins (for reviews, see
Mayer, 2005; Swanson et al., 2005). Functional AMPA
(alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid)
receptors are composed of GluA1-4 subunits, whereas kainate
receptors are composed of GluK1–5 subunits. Similarly,
NMDA (N-methyl-D-aspartate) receptors consist of a GluN1
subunit, together with GluN2A-D subunits and/or GluN3A-
B. In turn, mGluRs are classified as group I (mGluR1,
mGluR5), group II (mGluR2, mGluR3) and group III
(mGluR4, mGluR6–8) 7TM receptors. Glia express func-
tional iGluR and mGluR in both GM and WM (for recent
reviews, see (Bakiri et al., 2009; Matute, 2011). In particular,
astrocytes of the optic nerve have been shown to respond to
glutamate acting on both AMPA- and NMDA-type receptors,
as well as on group I mGluR, to induce an increase in astro-
glial [Ca21]i, which leads to the release of ATP by a mecha-
nism involving P2X7 receptors (Hamilton et al., 2008).
Similarly, oligodendrocytes have been shown to express in
their somata functional AMPA and kainate type receptors
throughout a wide range of developmental stages and species,
including humans (Matute et al., 2007a). In addition, imma-
ture and mature oligodendrocytes express in their processes
NMDA receptors, which can be activated during injury (Bal-
tan et al., 2008; Karadottir et al., 2005; Micu et al., 2006;
Salter and Fern, 2005). Moreover, oligodendrocytes also
express receptors from all three groups of mGluR, although
the expression level of these receptors appears to be develop-
mentally regulated and is reported to be very low in mature
oligodendrocytes (Deng et al., 2004). In turn, WM OPCs
express AMPA-type glutamate receptors which can be acti-
vated by glutamate released from mechanically activated astro-
cytes and from axons during action potential passage
(Hamilton et al., 2010; Kukley et al., 2007; Ziskin et al.,
2007). In contrast, little is known about glutamate receptors
in WM microglia, although glutamate is involved in the
transmission of death signals to microglia, to which they
respond by migrating to sites of neuronal injury (Sieger et al.,
2012). In GM, ramified microglia may express AMPA and
mGluR which can promote inflammation, chemotaxis, neuro-
protection or neurotoxicity (for reviews see Domercq et al.,
2013; Pocock and Kettenmann, 2007).
Glutamate Homeostasis
Glutamate uptake from the extracellular space is conducted
by specific glutamate transporters (GluT), and is essential for
the shaping of excitatory postsynaptic currents and for the
prevention of excitotoxic death due to overstimulation of glu-
tamate receptors (Rothstein et al., 1996). At least five gluta-
mate transporters have been cloned (Danbolt 2001), and of
these, GLT-1 (glutamate transporter 1, also known as
EAAT2—excitatory amino acid transporter 2) exhibits the
highest level of adult expression, overwhelmingly in astro-
cytes, and is responsible for most glutamate transport. GluTs
are also expressed by oligodendrocytes, although their expres-
sion has been less well characterized than in astrocytes. The
main transporter expressed by oligodendrocytes is GLAST
(glutamate aspartate transporter; also known as EAAT1). The
neuronal transporter, termed EAAC1 (excitatory amino acid
carrier 1, or EAAT3), is present in a subpopulation of adult
OPCs (Domercq et al., 1999). It appears that all WM macro-
glial cells differentially express the three major GluTs. These
transporters maintain basal levels of extracellular glutamate in
the range of 1 to 2 mM and prevent over-activation of gluta-
mate receptors under physiological conditions. In turn, GluT
can contribute to glutamate release in WM by reversing Na1-
dependent glutamate uptake in injured axons that suffer inter-
nal Na1 overload that reverses GluTs (Domercq et al., 1999;
Li et al., 1999; Longuemare et al., 1999). Moreover, given
the rising prominence of NMDA receptors in WM, and that
glycine is an obligatory co-agonist, it is important to note
that glycine transporters GLYT1/GLYT2 are expressed in
WM (Borowsky et al., 1993), and their activity will influence
the effects of glutamate signaling.
In addition, glutamate homeostasis is also regulated by
system x2c , a membrane-bound, Cl
2-dependent, Na1-inde-
pendent antiporter that mediates the cellular uptake of cystine
in a 1:1 exchange for glutamate (Conrad and Sato, 2012).
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The cystine/glutamate antiporter is the main neuronal source
of cystine, which is intracellularly converted to cysteine, the
rate-limiting substrate in glutathione synthesis. System x2c is
vital for antioxidant defence; its expression is rapidly upregu-
lated under oxidative stress, although its enhanced function
increases extracellular glutamate levels and may cause excito-
toxicity (Conrad and Sato, 2012). Notably, system x2c is
expressed by astrocytes, and by resting and activated microglia
(Domercq et al., 2007; Had-Aissouni, 2012; Pampliega et al.,
2011).
Glutamate Signaling in Axons
Axons are also endowed with glutamate receptors and gluta-
mate transporters. Native AMPA receptors in axons are formed
by the GluA4 subunit and kainate receptors are composed of
at least GluK1 and GluK2 subunits, which in all instances are
located in the internodes (Ouardouz et al., 2009a,b). In turn,
the major glutamate transporter expressed by axons is GLT-1,
although significant levels of GLAST are also present (Li et al.,
1999). Axonal AMPA receptors in spinal axons are weakly per-
meable to Ca21, the entry of which releases additional Ca21
from the axonal endoplasmic reticulum (ER) by opening intra-
cellular Ca21 channels known as ryanodine receptors—RyR
(Ouardouz et al., 2009b). In contrast, axonal kainate receptors
with the GluK1 subunit are coupled to phospholipase C
(PLC) activation (Ouardouz et al., 2009b). In addition, activa-
tion of kainate receptors with the GluK2 subunit induces a
small amount of Ca21 entry that stimulates nitric oxide syn-
thase (NOS), as well as a local depolarization that activates L-
type Ca21 channels, and subsequently RyR in the axoplasmic
reticulum (Ouardouz et al., 2009a). The functional signifi-
cance of these signaling mechanisms by glutamate receptors in
axons is unclear, although they may serve to amplify axonal
Ca21 signals that appear to be weak because of the limited
quantity of cation available in the narrow peri-axonal space
(Ouardouz et al., 2009a). Notably, local activation of axonal
AMPA/kainate receptors by glutamate released from periaxonal
astrocytes may increase the width of action potentials while
they travel down unmyelinated GM axons in the hippocampus
(Sasaki et al., 2011). In turn, the broadened action potential
triggers larger calcium elevations in presynaptic boutons and
facilitates synaptic transmission to postsynaptic neurons (Sasaki
et al., 2011). This glial-mediated action potential modification
might enable axonal computation through the geometry of
axon wiring.
Glutamate Signaling in Oligodendrocytes and
Myelin
Glutamate signaling in oligodendrocytes is also relevant to
myelination. Action potentials traveling along axons can
release glutamate in a vesicular manner, which promotes mye-
lin induction by stimulating the formation of cholesterol-rich
signaling domains between oligodendrocytes and axons and
increasing the local synthesis of major myelin proteins (Wake
et al., 2011). Mature CNS myelin sheaths express various
AMPA and kainate receptor subunits, as well as functional
NMDA receptors (reviewed in Stys, 2011). Curiously, these
NMDA receptors have unique properties: about half of them
are formed by receptors containing GluN2 subunits (probably
GluN1-GluN2C, D); the remaining NMDA receptors lack
the GluN2 subunit and therefore, are “glycine only” receptors
formed by GluN1-GluN3A subunits; and they display
reduced Ca21 permeability and Mg21 sensitivity. Interest-
ingly, immunogold labeling and electron microscopic exami-
nation revealed that both NMDA receptors are preferentially
localized at the inner and outer myelin loops. The presence
of the apparent machinery for vesicular release in axons (Alix
et al., 2008) and neurotransmitter receptors in the inner mye-
lin loop led to the hypothesis that myelin is the target for
neurotransmission across a putative axo-myelin “synapse,”
with the internodal axon cylinder acting as the presynaptic
element and the periaxonal space equivalent to the synaptic
cleft (Stys, 2011). In addition, WM possesses neurotransmit-
ter uptake systems in the axon membrane, particularly at the
nodes of Ranvier, as well as in the myelin (Stys, 2011).
Together, these findings suggest that communication between
axons and myelin shares many features of conventional chem-
ical synapses found in GM. This axon-myelin interplay may
provide a mechanism by which myelin-supporting oligoden-
drocytes increase the transfer of energy metabolites to fuel
electrically active fibres (Stys, 2011). Such a system might
seem at odds with evidence that glycogen (which is contained
exclusively in astrocytes) supports axons during intense activ-
ity or in the temporary absence of glucose (see Hirrlinger and
Nave, 2014). In fact, astrocytes and oligodendrocytes form
gap junctions, and may cooperate to provide a “supply line”
for the delivery of energy substrate to axons, whether they are
myelinated or not (Lee et al., 2012). Although this hypothesis
needs further experimental support, it provides novel ideas
that may be relevant to myelination and WM damage.
In addition to oligodendrocytes, activation of glutama-
tergic synapses in OPCs induces Ca21 entry, either directly
through the receptor channel or indirectly though Na1 entry
and depolarization resulting in activation of voltage-
dependent calcium channels and/or the reversal of Na1/
Ca21-exchanger (reviewed by Mangin and Gallo, 2011).
Neuron-OPC synapses are formed during spontaneous remye-
lination after demyelination, a feature suggesting that they
may act in the early steps of the myelination/remyelination
process (Etxeberria et al., 2010). This possibility is supported
by the fact that OPC lose their synapses as they differentiate
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into myelinating oligodendrocytes (Kukley et al., 2010).
Therefore, it is plausible that glutamatergic synapses inhibit
OPC proliferation in an activity-dependent manner (Mangin
and Gallo, 2011). Indeed, there is evidence that glutamate
inhibits OPC proliferation, increases their migration speed,
and inhibits their ability to differentiate into oligodendrocytes
in vitro (reviewed in (Mangin and Gallo, 2011). In apparent
contradiction with this idea, recent data support the notion
that glutamate acting at NMDA receptors may contribute to
oligodendrocyte maturation (Cavaliere et al., 2012).
Despite this wealth of information, direct evidence that
oligodendroglial glutamate receptors have a physiological role
in regulating myelination in vivo is lacking.
Glutamate Signaling in WM Injury and Repair
Glutamate and Excitotoxicity. The term excitotoxicity was
coined more than 50 years ago, and refers to neuronal dam-
age by excessive activation of glutamate ionotropic receptors.
Excitotoxicity is also highly relevant to WM damage, where
receptor-mediated glutamate toxicity is clearly involved in cer-
tain pathological conditions (Matute 2011; Ransom and Bal-
tan 2009). Over-activation of AMPA and kainate receptors
causes oligodendrocyte death and primary and/or secondary
myelin destruction (Matute 2011). The influx of Ca21 upon
receptor activation and the ensuing accumulation of Ca21
within mitochondria are central to this process. These events
lead to mitochondrial depolarization, increased production of
radical oxygen species, and the release of pro-apoptotic fac-
tors, which in turn activate caspase-dependent and -independ-
ent oligodendrocyte death (Sanchez-Gomez et al., 2003).
Detailed studies of oligodendrocyte excitotoxicity have shown
that Bax and calpain are essential intermediaries (Sanchez-
Gomez et al., 2011), and that Ca21-induced calcium release
through RyR also contributes to mitochondrial dysfunction
and ER stress (Ruiz et al., 2010). However, the mechanisms
triggered by NMDA receptor-mediated insults to oligoden-
drocytes have not yet been studied in detail.
The direct inhibition of glutamate uptake in axonal
tracts leads to oligodendroglial loss, massive demyelination,
and severe axonal damage (Domercq et al., 2005). Other fac-
tors that may contribute to perturbing glutamate homeostasis
and cause WM damage include: altered activity of the
glutamate-producing enzyme glutaminase in activated macro-
phages/microglia in close proximity to dystrophic axons
(Werner et al., 2001); and reduced expression of the gluta-
mate transporters GLAST and GLT-1 in oligodendrocytes as
a consequence of enhanced exposure to the proinflammatory
cytokine tumour necrosis factor a (Pitt et al., 2003) and oxi-
dative stress (Domercq et al., 2007). Moreover, activated
microglia increase their own expression of xCT (glutamate-
cystine exchange transporter), which contributes further to
increasing glutamate levels and glutamate toxicity (Domercq
et al., 2007). In turn, excessive activation of internodal axonal
glutamate receptors may induce the release of substantial
amounts of calcium from axoplasmic ER and activate
calcium-dependent enzymes that ultimately ignite the collapse
of the axon (Stirling and Stys, 2010).
Glutamate and Ischemia. Damage of central WM is a
major cause of functional disability in cerebrovascular disease.
Injury to WM as a consequence of hypoxic-ischemic injury
occurs in periventricular leukomalacia (PVL) in neonates and
in stroke and cardiac arrest in adults, as well as in vascular
dementia in the aging brain. The metabolic rate of WM is only
modestly lower than that of GM, and animal studies suggest
that WM can be damaged by even brief ischemia (Pantoni
et al., 1996). Ischemic insults typically result in transmembrane
ion gradient breakdown and membrane depolarization, leading
ultimately to toxic intracellular Ca21 overload. The final stage
is the activation of Ca21-dependent enzymes (e.g. calpains,
phospholipases, and other enzymes), resulting in irreversible
damage of WM glia and axons (Hamner et al., 2011; Stys
et al., 1992; Tsutsui and Stys, 2013).
Glutamate excitotoxicity contributes to WM demise
during ischemia and putative subsequent reperfusion. Imma-
ture and differentiated oligodendrocytes are very sensitive to
transient oxygen and glucose deprivation (Fern and Moller,
2000). Both cell types can be partially protected from irre-
versible ischemic injury by reducing extracellular Ca21 or by
AMPA/kainate receptor antagonists, but not by the blockade
of Ca21 influx through Ca21 voltage-dependent channels or
Na1/Ca21exchanger, which suggests that Ca21 entry through
the receptor channel is sufficient to initiate cell demise. Nota-
bly, simulated ischemia in young animals induces an inward
current in oligodendrocytes that is partly mediated by
NMDA and AMPA/kainate receptors (Karadottir et al.,
2005), and which is directly toxic to the cell processes (Salter
and Fern, 2005). In addition, Ca21 levels also increase in
myelin itself during ischemia (an effect that is abolished by
broad-spectrum NMDA receptor antagonists), causing
ultrastructural damage to the myelin sheath (Micu et al.,
2006).
WM becomes intrinsically more vulnerable to ischemia
with age and the mechanisms of glutamate-mediated damage
change (Baltan et al., 2008). Thus, ischemic WM injury in
older mice is predominately mediated by glutamate release
through reverse glutamate transport (probably from astrocytes)
and the ensuing activation of AMPA/kainate-type glutamate
receptors (Baltan et al., 2008). Intriguingly, blockade of
NMDA receptors aggravates the outcome of ischemia in older
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animals (Baltan et al., 2008), a feature which may have to do
with a potential role of these receptors in energy support.
Perinatal Ischemia. PVL is the major neuropathological
lesion in premature infants, and involves focal WM necrosis
and subsequent hypomyelination. The pathophysiology of
PVL is multifactorial and includes hypoxia-ischemia2induced
glutamate excitotoxicity, oxidative stress, and inflammation
(Volpe, 2009) (see Back and Rosenberg, 2014). Injury to
OPCs caused in part by glutamate contributes to the patho-
genesis of myelination disturbances in PVL (Back and Riv-
kees, 2004). In the immature human brain, the susceptibility
of developing oligodendrocytes to hypoxia-ischemia correlates
with their expression of glutamate receptors of the AMPA
receptor subtype (Talos et al., 2006), and systemic adminis-
tration of AMPA receptor antagonists attenuates injury in a
rat model of PVL (Follett et al., 2004). In addition, develop-
ing oligodendrocytes also express NMDA receptors; their
blockade with memantine attenuates oligodendrocyte loss and
prevents the long-term reduction in cerebral mantle thickness
that is observed in experimental PVL (Manning et al., 2008).
Intriguingly, synapses between axons and OPCs are quickly
and profoundly damaged in PVL models, an observation that
outlines the relevance of these synaptic contacts to WM integ-
rity during development (Shen et al., 2012).
Ischemic injury to axons is also a feature of PVL; it
occurs early in local and diffuse damage associated with this
pathology (Haynes et al., 2008). Interestingly, experimental
ischemia in immature axons produces action potential failure
and focal breakdown of the axolemma of small premyelinated
axons at sites of contact with oligodendrocytic processes,
which are also disrupted (Alix and Fern 2009). Axon damage
is prevented by NMDA and AMPA/kainate receptor blockers,
suggesting that glutamate receptor-mediated injury to oligo-
dendrocytic processes in contact with premyelinated axons
precedes disruption of the underlying axon and/or that pre-
myelinated axons also express GluRs (Alix and Fern, 2009).
Multiple Sclerosis. The major demyelinating disease of the
CNS is MS, which is the foremost disabling pathology
among young adults (Lassmann, 2014). MS is a chronic,
degenerative disease that is characterized by focal lesions with
inflammation, demyelination, infiltration of immune cells,
oligodendrocyte death, and axonal degeneration (Prineas
et al., 2001). It is widely accepted that the aetiology of this
illness has autoimmune and inflammatory grounds, and that
a derailment of the immune system leads to cell- and
antibody-mediated attacks on myelin. Both genetic and envi-
ronmental factors contribute to MS susceptibility (Zamvil
and Steinman, 2003). Among them, primary and/or second-
ary alterations in glutamate signaling cause excitotoxicity,
which in turn contributes to MS pathology. Numerous stud-
ies conducted in cellular and animal models of MS, as well as
in post-mortem brain and in patients, have indicated that
excitotoxicity mediated by Ca21-permeable glutamate recep-
tors contributes to oligodendrocyte death, demyelination, and
tissue damage (Matute et al., 2001; Srinivasan et al., 2005;
Vallejo-Illarramendi et al., 2006). In particular, experimental
autoimmune encephalomyelitis (EAE), a mouse disease model
that exhibits clinical and pathological features of MS, is allevi-
ated by AMPA and kainate receptor antagonists (Pitt et al.,
2000; Smith et al., 2000). In contrast, blockade of NMDA
receptors with MK-801 does not attenuate chronic EAE
symptoms (Matute, 2010), and conditional deletion of
GluN1 in oligodendrocytes does not alter the onset and
course of symptoms in this experimental model of MS (Guo
et al., 2012; but see Graselli et al., 2013). Remarkably, block-
ade of these receptors in combination with anti-inflammatory
agents is effective even at an advanced stage of unremitting
EAE, as assessed by increased oligodendrocyte survival and
remyelination, and corresponding decreased paralysis, inflam-
mation, CNS apoptosis, and axonal damage (Kanwar et al.,
2004). Importantly, a recent genome-wide association screen-
ing study identified associated alleles in AMPA receptor genes
in MS patients who exhibited the highest levels of glutamate
and brain volume loss (Baranzini et al., 2010). These findings
provided a novel quantitative endophenotype that may help
clarify the pathophysiology of the heterogeneity of clinical
expression in MS.
Glutamate levels are increased in the human MS brain
(Srinivasan et al., 2005) as a consequence of reduced expres-
sion of the glutamate transporters GLAST and GLT-1 (Pam-
pliega et al., 2008; Vallejo-Illarramendi et al., 2006). Another
mechanism accounting for glutamate dyshomeostasis is
genetic variability in the promoter of the major glutamate
transporter, GLT-1, which results in lower transporter expres-
sion (Pampliega et al., 2008). In turn, upregulation of xCT
in the monocyte-macrophage-microglia lineage is associated
with immune activation in both MS and EAE (Pampliega
et al., 2011).
Non-toxic glutamate concentrations also contribute to
demyelinating pathology by inducing oligodendrocyte death
by sensitizing oligodendrocytes to complement attack (Alberdi
et al., 2006). Intriguingly, complement toxicity is induced by
the activation of kainate, but not of AMPA, NMDA, or
metabotropic glutamate receptors. Oligodendrocyte death by
complement requires the formation of the membrane attack
complex, which in turn increases membrane conductance and
induces Ca21 overload and mitochondrial depolarization, as
well as an increase in the level of reactive oxygen species
(Alberdi et al., 2006). Sensitization by glutamate to comple-
ment attack may initiate MS lesions with massive oligoden-
drocyte apoptosis (Barnett and Prineas, 2004).
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Physical Trauma. Traumatic injury to the CNS inevitably
involves damage to WM and causes primary mechanical
destruction of glia and axons (Kou and VandeVord, 2014). In
addition, secondary impairment of tissue occurs as a conse-
quence of a prolonged pathological response involving
chronic inflammation, microglial activation, and astroglial
scar formation. This prolonged response can ultimately result
in the development of a large cavity at the site of the lesion
and persistent functional deficits (Dumont et al., 2001). Tis-
sue destruction after traumatic brain injury leads to the
release of large amounts of glutamate, which cause Ca21-
dependent excitotoxic damage to white matter astrocytes, oli-
godendrocytes, and myelin, but not to axons (Li and Stys,
2000). Indeed, glutamate dysregulation is centrally involved
in the outcome following traumatic spinal cord injury. After
thoracic crush of the spinal cord, mice heterozygous for the
astrocytic glutamate transporter GLT-1 exhibit attenuated
recovery of hindlimb motor function, increased lesion size,
and reduced tissue sparing (Lepore et al., 2011). These find-
ings indicate that glutamate uptake by astrocytes limits sec-
ondary damage after CNS traumatic injury, and that
promoting glutamate transporter expression and function may
favor postlesion recovery.
Purine Signaling in WM
Purine Receptors
Glial cells express multiple purine receptors (Butt, 2011).
Adenosine acts via four subtypes of G-protein coupled recep-
tors (A1 and A3 receptors inhibit cAMP via Gi/o, whereas
A2A and A2B receptors stimulate cAMP via Gs), and all have
been described in astrocytes, OPC and microglia, but they
appear to be downregulated in differentiated oligodendrocytes
(Abbracchio et al., 2009; Ciccarelli et al., 2001; Stevens et al.,
2002). Adenosine receptors mediate the repulsive effects of
ATP/adenosine on microglia (Gyoneva et al., 2009), evoke
Ca21 signals in optic nerve astrocytes and probably OPC in
situ (Hamilton et al., 2008), and regulate OPC differentiation
and myelination (Stevens et al., 2002). Immunocytochemical
evidence for A1 receptors has been reported in adult rat cor-
pus callosum axons and their activation modulated axon con-
duction (Swanson et al., 1998). Otherwise, there is little
direct knowledge of the normal physiological functions for
adenosine receptors in WM. Adenosine is very important in
pathology, since its levels increase rapidly with tissue ischemia
and inflammation. Adenosine receptors contribute to WM
injury in the preterm infant by altering oligodendrocyte
development and are therapeutic targets in stroke and MS
(Matute, 2011; Matute et al., 2012; Rissanen et al., 2013;
Rivkees and Wendler, 2011).
A key feature of glia throughout the CNS is their
expression of functional ionotropic P2X and metabotropic
P2Y receptors, which are the substrate for glial Ca21 signal-
ing (James and Butt, 2002). P2X receptors comprise seven
subtypes (P2X1–7), which are ligand-gated channels permea-
ble to Na1, K1 and Ca21 (Burnstock, 2007). Glia may
express all P2X subtypes, but P2X1-P2X4 and P2X7 may
predominate in astrocytes (Ashour and Deuchars, 2004;
Franke et al., 2001; Kanjhan et al., 1999; Loesch and Burn-
stock, 1998), oligodendrocytes and OPCs (Agresti et al.,
2005a,b; Matute et al., 2007), and microglia (Franke et al.,
2004; Tsuda et al., 2003). There is direct immunohistochemi-
cal evidence of P2X7 receptors in oligodendrocytes in vivo,
and they have been shown to mediate raised [Ca21]i in WM
astrocytes in situ and oligodendrocytes in vitro (Hamilton
et al., 2008, 2010; James and Butt, 2001; Matute et al.,
2007b). The P2X7 receptor subtype is capable of pore forma-
tion, resulting in sustained influx of Ca21 and mediates glial
pathological responses, in particular the loss of oligodendro-
cytes and myelin in ischemia and demyelination (Domercq
et al., 2010; Matute and Cavaliere, 2011; Matute et al.,
2007b). Interestingly, a decrease in P2X7 receptor expression
has been reported in cultured OPCs and subcortical white
matter in a hypoxic-ischemic injury model in postnatal rats
(Wang et al., 2009), although the pathophysiological signifi-
cance of these observations is unclear. Microglia have also
been shown to express P2X4 receptors in the developing cor-
pus callosum, where they have a role in inducing activation
during ischemia, but their expression was markedly down-
regulated postnatally (Li et al., 2011).
P2Y are 7TM receptors and eight subtypes have been
cloned in mammals, with differential sensitivities to the ade-
nine nucleotides ATP/ADP (P2Y1,11,12,13), the uracil nucle-
otides UTP/UDP (P2Y4,6), the adenine and uracil
nucleotides (P2Y2), and UDP-glucose (P2Y14). All P2Y
receptors are G-protein-coupled and activate phospholipase C
(PLC)/inositol triphosphate (InsP3) and Ca21-release from
the smooth ER via Galpha(q/11) (P2Y1, P2Y2, P2Y4, P2Y6,
and P2Y11), or regulate adenylyl cyclase via Galpha(s) and
Galpha (i/o) proteins (P2Y12, P2Y13, and P2Y14) (Burn-
stock 2007). P2Y receptors are broadly distributed in glia,
although the specific subtypes expressed in WM are less
clearly defined (James and Butt, 2002). Prominent immuno-
labeling for P2Y1 receptors has been demonstrated in WM
oligodendrocytes and astrocytes (Moran-Jimenez and Matute,
2000) and they are the primary receptors involved in ATP-
mediated Ca21 signals in optic nerve astrocytes and most
likely oligodendrocytes and OPCs in situ (Hamilton et al.,
2008, 2010; James and Butt, 2002). In OPCs, P2Y1 receptor
activation in vitro stimulates cell migration and development
(Agresti et al., 2005). Notably, P2Y12 receptors are enriched
in oligodendrocytes and are involved in demyelination and
MS (Amadio et al., 2006, 2010). The P2Y-like receptor
Butt et al.: Neurotransmitter Signaling in White Matter
November 2014 1771
GPR17 is highly expressed in OPCs and mediates their
response to uracil nucleotides (e.g. UDP-glucose) and
cysteinyl-leukotrienes (e.g. LTD4 and LTC4), which may be
important during development and injury (Boda et al., 2011;
Fumagalli et al., 2011). GPR17 is increased in animal models
of ischemia and trauma, as well as human traumatic brain
injury, where it may mediate microgliosis, as well as adenine
nucleotide-induced cytotoxicity of OPCs (Ceruti et al., 2009,
2011; Franke et al., 2013; Zhao et al., 2011).
Mechanisms for ATP Release in WM
Studies by the Butt and Matute groups have demonstrated ATP
mediates raised Ca21 in optic nerve astrocytes in situ via a wide
range of receptors (see above) and that oligodendrocytes at least
in vitro respond in the same way. The primary source of endog-
enous ATP in WM is not resolved, but in the optic nerve ATP
is released during action potential propagation and astrocytes
release ATP following mechanical stimulation (Hamilton et al.,
2008, 2010). Optic nerve astrocytes express P2X7 receptors,
which are implicated in ATP release (Hamilton et al., 2008),
and astrocytes widely express connexin-43, pannexin-1, and
volume-regulated anion channels, which are additional poten-
tial mechanisms of neurotransmitter release in astrocytes (Par-
pura et al., 2004). Astrocytes may also release ATP by vesicular
exocytosis (Montana et al., 2006), although there is no direct
evidence for this in WM. WM axons have not been shown to
release ATP, although it is conceivable they could release ATP
by vesicular mechanisms either in specific vesicles or as a
cotransmitter (see above for glutamate).
Physiological Functions for ATP Signaling in WM
WM astrocytes extend fine finger-like projections that form
points of contact with nodes of Ranvier (Butt et al., 1994), the
sites of action potential propagation and in myelinated tracts
the only possible site of direct axon-to-astrocyte signaling. Axo-
nal electrical activity triggers astrocyte calcium signals, which
in turn triggers their release of ATP to propagate and amplify
the initial calcium signal through the glial network (Hamilton
et al., 2008, 2010). Most evidence indicates that astrocyte sig-
naling spreads as a circular wave in all directions from a focal
source, through gap junctions and by the release of ATP to
activate glial receptors in a “spillover” or volume transmission
manner. The ATP-mediated rise in astrocyte calcium may
stimulate them to release glutamate or other neurotransmitters,
such as GABA and acetylcholine (ACh) (see below), which
have been shown to act on axonal receptors to modulate their
conduction properties (Sakatani et al., 1994; Sasaki et al.,
2011; Sun and Chiu, 1999; Zhang et al., 2004). In addition,
intercellular Ca21 waves in astrocytes have been shown to trig-
ger microglial Ca21 responses through the release of ATP
(Schipke et al., 2002; Verderio and Matteoli, 2001), which is
central to their injury response (Maeda et al., 2010; Tsuda
et al., 2010). Furthermore, ATP is a potent vasoconstrictor
and its metabolite adenosine is a potent vasodilator, and so
their release by astrocytes at the gliovascular interface could
provide a mechanism for local regulation of blood flow, both
physiologically and in pathology.
There is abundant evidence that ATP mediates Ca21
signals in oligodendrocytes via both P2Y1 and P2X7 receptor
subtypes (Alberdi et al., 2005; James and Butt, 2001; Kirischuk
et al., 1995). Activation of P2X7 receptors can result in demye-
lination and the loss of oligodendrocytes and may have a partic-
ular role in pathological conditions such as ischemia and MS
(see below). Direct evidence of a physiological role for ATP sig-
naling in oligodendrocytes is lacking, due to the difficulty of
calcium imaging from oligodendrocytes in situ and distinguish-
ing between direct and indirect actions of any stimulus, but it
seems inconceivable that ATP released by astrocytes and during
axonal action potential propagation would not activate these
receptors on oligodendrocytes. It is reasonable to conclude that
ATP-mediated signaling is physiologically important in oligo-
dendrocytes, possibly as a communications pathway by which
axonal activity helps maintains myelin production by oligoden-
drocytes, in a way similar to that described in developing WM
(Ishibashi et al., 2006; Stevens et al., 2002; Wake et al., 2011).
ATP and Adenosine Mediate Axonal Control of
Myelination
OPCs form intimate contacts with axons at presumptive
“synapses” and at nodes of Ranvier in unmyelinated and
myelinated axons (Butt et al., 1999; Hamilton et al., 2010;
Ziskin et al., 2007), and respond by raised intracellular cal-
cium to ATP and adenosine released during axonal electrical
activity (Hamilton et al., 2010; Stevens et al., 2002). In situ
studies indicate adenosine acts to inhibit OPC proliferation
and promote their differentiation and myelination (Stevens
et al., 2002), whereas ATP acts on astrocytes to trigger the
release of leukemia inhibitory factor (LIF), which in turn acts
on oligodendrocytes to promote myelination (Ishibashi et al.,
2006). In addition, there is evidence in culture that adenosine
acting via A1 receptors and ATP acting via P2Y1 and P2X7
receptors regulate the migration, proliferation and differentia-
tion of OPCs (Agresti et al., 2005; Othman et al., 2003). As
noted above for glutamate, axonal release of ATP and/or
adenosine may be important in remyelination and repair (see
Franklin and Gallo, 2014), since demyelinated axons form
synapses with adult-born OPCs in an experimental model of
demyelination (Etxeberria et al., 2010).
Purine Receptors and WM Pathology
Adenosine, P2X, and P2Y receptors are implicated in reactive
astrogliosis, demyelination and microglial activation (Matute
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and Cavaliere, 2011). The majority of studies have been on GM
and these are likely to inform on processes in WM, but in gen-
eral direct experimental evidence in WM is lacking. As noted
above, adenosine and P2X7 receptors are implicated in oligoden-
drocyte/myelin loss in ischemia and MS in WM (Domercq
et al., 2010; Matute and Cavaliere, 2011; Matute et al., 2007b).
In GM, P2Y1, and P2Y12 receptors are involved in astrogliosis
in vivo (Franke et al., 2001), and the P2X receptor antagonist
PPADS significantly decreases astrogliosis following spinal cord
injury in vivo (Rodriquez-Zayas et al., 2012). However, P2X4
and P2Y12 receptors also regulate the microglial injury response
(Franke et al., 2013), and the latter are expressed by oligoden-
drocytes/myelin (Amadio et al., 2006), making it difficult to dis-
tinguish specific cellular responses in vivo.
Non-Glutamatergic/Purinergic
Neurotransmitters in WM
As described above, there are a variety of developmental func-
tions now understood for WM glutamatergic/purinergic recep-
tors (Table 1), but functional receptors for GABA-A/B, glycine
and to a lesser extent nicotinic, 5-HT, dopamine and adreno-
receptors have also been reported in WM, although their func-
tions remain mysterious (Tables 2 and 3). In a recent study, Fern
and colleagues found that mRNA for three quarters of receptor
subunits from a panel of non-glutamatergic/purinergic receptors
were robustly expressed in WM glial cells, with some found at
higher levels than in GM structures (Domingues et al., 2010). It
seems likely that such wide-scale expression in glia, together with
strong evidence for functional expression in some axons, is physi-
ological, possibly in the same manner as described for glutamate
and ATP. However, extrapolation from studies based on GM glia
should be avoided when considering WM glia; for example it
has been pointed out by Bergles et al. (2010) that the GABA-A
receptor currents found in OPC in GM areas have not been seen
in corpus callosum using approaches that should have detected
them if present (Kukley et al., 2007; Ziskin et al., 2007).
GABA and Glycine
It has been estimated that 75% of human synapses are
GABAergic (Chang et al., 2003). It is therefore surprising
that MRS suggests that the GABA concentration in human
WM is 50% of that in GM, where the vast majority of
known GABAergic synapses are located (Choi et al., 2007;
Jensen et al., 2005). A similarly high percentage has been
found for WM glycine (Banerjee et al., 2012), and biochemi-
cal analysis of adult pig brain gives values of 50 and
100%, respectively (Henjum and Hassel, 2007a, 2007b).
Data on extracellular neurotransmitter concentrations or
physiological neurotransmitter release in WM are lacking,
although ischemia-induced release of neurotransmitters such
as GABA has been documented (Shimada et al., 1993).
GABA is localized in neonatal rat optic nerve glia, with
expression down-regulated with maturation (Ochi et al.,
1993; Sakatani et al., 1992), although this may be due to
increased rates of GABA degradation since numerous
GABA1 WM astrocytes are apparent in adult rat following
inhibition of the catabolic enzyme GABA-alpha-ketoglutaric
acid aminotransferase (Bull and Blomqvist, 1991). High con-
centrations of neurotransmitter such as GABA and glycine are
also present in a sub-population of mature WM axons in sev-
eral species (Carlton et al., 1996; Davanger et al., 1991; Rog-
ers and Pow, 1995; Todd and Sullivan, 1990; van den Pol
and Gorcs, 1988; Wilson et al., 1996).
Block of GABA uptake mimics the effects of GABA
upon axon conduction in the neonatal rat optic nerve (Saka-
tani et al., 1991), while block of catecholamine uptake
mimics the effect of nor-adrenaline (Nikolaeva et al., 2009);
observations consistent with tonic operation of functional
neurotransmitter uptake in the tissue. mRNA for GAT 1–3
GABA transporters is present in neonatal and adult rat optic
nerve (Howd et al., 1997), while protein expression levels for
GAT-2 are high in subcortical adult rat WM (Conti et al.,
1999). GAT-1 protein expression is absent from monkey and
human adult optic nerve (Casini et al., 2006), but expression
can be robust in axons of several WM structures in rat and
man, with no apparent expression in accompanying glia
(Conti et al., 1998; Minelli et al., 1995; Yan and Ribak,
1998). Several other studies report low or zero GAT expres-
sion in various rat WM structures (e.g. Durkin et al., 1995;
Itouji et al., 1996), although species differences may be signif-
icant with high levels of GAT-3 expression reported in oligo-
dendrocytes in cat, monkey and man (see Pow et al., 2005).
Glycine transporters GLYT1/GLYT2 are expressed in WM
(Borowsky et al., 1993), including glial cells in rat spinal cord
WM (Zafra et al., 1995). GABA and glycine uptake rates in
adult pig WM proteoliposomes approach 20% and 100%
of the comparable levels in GM respectively, and are sensitive
to selective inhibitors (Henjum and Hassel, 2007a, 2007b).
There is therefore strong evidence for GABA and glycine
in WM axons and glia and functional neurotransmitter uptake
into WM glia both in the neonate and the adult, but species
and regional variations appear to be quite significant. In light
of these observations, it is interesting that vigabatrin, a GABA
elevator in clinical practice as an anti-epileptic, can produce
selective WM toxicity involving myelin splitting (see Walzer
et al., 2011). Elevated glycine levels due to genetic mutations
are also associated with a variety of WM pathologies (de Kon-
ing et al., 2000; Press et al., 1989; van der Knaap et al., 1999).
Such observations highlight the clinical relevance of non-gluta-
matergic/purinergic WM neurotransmitters, and confirm func-
tional uptake in the tissue; the actions of glycine may be
primarily via NMDA receptors (see above), and so it can be
considered an element of glutamatergic signaling.
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Other Neurotransmitters
There is less information regarding adreno-receptors, nicotinic
cholinergic, dopaminergic and serotonergic receptors in WM
than for GABA and glycine. Nicotinic agonists are protective
against injury in developing WM, having complex actions via
several receptor types (Laudenbach et al., 2002; Paris et al.,
2006). Expression of the a2 receptor is widespread in develop-
ing WM structures in rat, but declines to low levels in adult
(Happe et al., 2004); expression is functional being associated
with elevated GTPcS binding indicative of G-protein stimula-
tion (Sanders et al., 2005). There is good evidence for traffick-
ing of various nicotinic receptor proteins along optic nerve
axons (Cox et al., 2008) and nicotinic receptor binding is par-
ticularly high in human and non-human primate WM struc-
tures such as sub-cortical WM (Ding et al., 2004). Serotonin
has been seen in adult monkey WM axons (Westlund et al.,
1992), and receptor expression reported in adult rat spinal cord
WM astrocytes (Maxishima et al., 2001). The functional signif-
icance of these observations is not clear. In addition, a1 and b2
adreno-receptors have been described in the rabbit, rat, and
human optic nerve, and b2 receptors are up regulated after
optic nerve transection (Mantyh et al., 1995). b2 receptors are
present in GFAP1 astrocytes in normal appearing WM from
MS patients, but appears to be lost in plaques (De Keyser et al.,
1999, 2001, 2004). This may have significant consequences for
disease progression by either affecting immunoresponses or dis-
ruption of white matter energy metabolism (Cambron et al.,
2012). Dopamine and noradrenaline can evoke physiological
responses in rat spinal cord WM via D1 or a1/a2/b adreno-
receptors respectively, and there is some evidence for low levels
of D1 receptor expression in human WM (Sovago et al., 2005;
Venugopalan et al., 2006). Catecholamines can influence ische-
mic injury in adult WM and are toxic to developing WM
(Constantinou and Fern, 2009; Nikolaeva et al., 2009); the role
of neurotransmitters in WM pathology is covered in a compan-
ion review in this volume.
Physiological Functions of Nonglutamatergic/
Purinergic Neurotransmitter Systems in WM
We have summarized data consistent with WM expression of
a number of non-glutamatergic/purinergic neurotransmitter
systems in Tables 2 and 3. In general, developing WM axons
express a wide range of receptors and their activation results
in axonal depolarization and reduces excitability. Immuno-
staining and PCR confirm expression of multiple receptor
types in in vivo in astrocytes and oligodendrocytes, and func-
tional electrophysiological and imaging studies suggest they
may be developmentally regulated. A number of functional
glial uptake mechanisms have also been convincingly
reported. To date, it has not been possible to specifically tar-
get WM and so it remains speculative as to why WM contain
such varied neurotransmitter signaling mechanisms. Most of
these neurotransmitters have been shown to affect OPCs and
their differentiation in one manner or other: for example,
activation of GABA-AR inhibits proliferation in the early oli-
godendroglial lineage (Yuan et al., 1998), whereas mAChR
activation significantly increases OPC proliferation and inhib-
its their differentiation into myelinating oligodendrocytes (De
Angelis et al., 2011). An alternative possible physiological
function of diverse neurotransmitter signaling comes from
non-mammalian experimental models, such as the lobster and
crab, where the neurotransmitters dopamine and 5-HT are
capable of axonal action potential initiation, independently of
actions at somata and synapses (Ballo et al., 2010; Meyrand
et al., 1992; Verdier et al., 2003). Evidence is gathering that
modulation of the excitability of axons in mammalian CNS
may also have functional implications, e.g. in WM via nico-
tinic receptors in some pathways (Kawai et al., 2007) and in
neonatal rat brain stem WM via GABA-A receptor activation
(Kress and Mennerick 2009). It is important to note that this
is distinct from classical pre-synaptic effects, where axonal
receptors modulate synaptic neurotransmitter release via local
action (Trigo et al., 2008).
Summary and Conclusions
It is now clear that neurotransmitter signaling is a prominent fea-
ture of myelinated axons in WM and GM, and across a wide
range of species including humans. This is notable, because WM
is characterised in general by a lack of neurons and synapses, and
so neurotransmitter signaling has physiological functions other
than neuron-to-neuron communication. A key feature in WM is
the apparent predominance of glutamate- and ATP-mediated sig-
naling mechanisms, but this may reflect the physiological techni-
ques we have at our disposal, rather than the true pre-eminence
of these neurotransmitters. A common theme is that neurotrans-
mitters evoke Ca21 signals in WM glia, which may be important
in the homeostatic functions of astrocytes, whereas in oligoden-
drocytes they may have specific roles during differentiation and
myelination. There is evidence for direct effects of neurotrans-
mitters on axons and this may be important for strengthening
conduction of action potentials and maintaining signal integrity
along potentially very long projections. Perhaps the most surpris-
ing aspect is the diversity of neurotransmitter signaling in WM.
Such diversity at GM synapses reflects differences in excitatory,
inhibitory and neuromodulatory functions, which is the basis for
the phenomenal complexity of neuronal network activity. Why
the WM requires so many neurotransmitters is one of the fasci-
nating questions facing those working in the field. A radical
hypothesis is that diverse neurotransmitters are capable of axonal
action potential initiation and/or modulation of axon excitability.
It is possible, therefore, that WM neurotransmitters are involved
in some form of information processing.
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